Get the Stockscreener App
0.00
100.00%
-115.07
Arcellx Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
See More
Previous Close:
$115.07
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$6.73B
Revenue:
$22.29M
Net Income/Loss:
$-228.93M
P/E Ratio:
0.00
EPS:
-4.0547
Net Cash Flow:
$-212.59M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$115.13
52-Week Range:
$0.00
$115.13
Arcellx Inc Stock (ACLX) Company Profile
Name
Arcellx Inc
Sector
Industry
Phone
240-327-0603
Address
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
0.00 | 6.73B | 22.29M | -228.93M | -212.59M | -4.0547 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-22-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-16-25 | Initiated | Stifel | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Sep-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Mar-07-24 | Initiated | Morgan Stanley | Overweight |
| Jan-04-24 | Reiterated | Needham | Buy |
| Dec-19-23 | Initiated | Scotiabank | Sector Outperform |
| Oct-30-23 | Initiated | TD Cowen | Outperform |
| Oct-17-23 | Initiated | UBS | Buy |
| May-18-23 | Initiated | Truist | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
| Mar-14-23 | Initiated | Stifel | Buy |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-13-22 | Resumed | BofA Securities | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-27-22 | Initiated | Needham | Buy |
| Jul-20-22 | Initiated | Canaccord Genuity | Buy |
| Mar-01-22 | Initiated | BofA Securities | Buy |
| Mar-01-22 | Initiated | SVB Leerink | Outperform |
View All
Arcellx Inc Stock (ACLX) Latest News
Gilead’s HIV Priority Review And Arcellx Deal Refocus Long‑Term Story - Yahoo Finance
Arcellx, Inc. Financial Disclosures & Filings - TradingView
Pictet Asset Management Holding SA Decreases Stake in Arcellx, Inc. $ACLX - MarketBeat
Gilead buys Arcellx (ACLX) for $115 per share plus $5 CVR - Stock Titan
MSN Money - MSN
Arcellx (ACLX) to Release Earnings on Thursday - MarketBeat
Arcellx's (ACLX) "Neutral" Rating Reiterated at Cantor Fitzgerald - MarketBeat
Are medical stocks lagging Arcellx (ACLX) this year? - MSN
Arcellx (NASDAQ:ACLX) Sets New 12-Month HighTime to Buy? - MarketBeat
Gilead Sciences (GILD) Closes $7.8B Arcellx Buyout — What Investors Need to Know - MEXC
Arcellx (ACLX) director-linked fund exits as Gilead buyout closes - Stock Titan
Arcellx Acquired in Cash-and-CVR Deal, Going Private - TipRanks
Arcellx (NASDAQ: ACLX) director cashes out in Gilead merger deal - Stock Titan
Gilead deal cashes out Arcellx (NASDAQ: ACLX) director options - Stock Titan
[Form 4] Arcellx, Inc. Insider Trading Activity - Stock Titan
Arcellx (ACLX) director cancels stock options for cash and CVRs in Gilead merger - Stock Titan
Arcellx (ACLX) director’s shares and options cashed out in Gilead deal - Stock Titan
Arcellx (ACLX) CFO logs tender-offer share disposal and equity award conversions in Gilead merger - Stock Titan
Arcellx (ACLX) CMO reshapes stock and options in Gilead deal - Stock Titan
Arcellx (ACLX) equity cashed out at $115 plus CVRs in Gilead deal - Stock Titan
Gilead completes Arcellx merger; Arcellx (NASDAQ: ACLX) deregisters S-3 - Stock Titan
Gilead buys Arcellx (ACLX) for $115 cash plus CVR; holder at 0% - Stock Titan
Gilead buys Arcellx (NASDAQ: ACLX) in $7.1B cash and CVR deal - Stock Titan
Gilead Sciences (GILD) Stock Lands $7.8B Arcellx Deal — Is This the Buy Opportunity? - MEXC Exchange
Gilead completes $7.8 billion acquisition of Arcellx By Investing.com - Investing.com India
Gilead Sciences, Inc. completed the acquisition of 77.2% stake in Arcellx, Inc. from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others. - marketscreener.com
Gilead Sciences (GILD) Completes Acquisition of Arcellx, Inc. - GuruFocus
Gilead Sciences completes acquisition of Arcellx ahead of potential commercial launch of Anito-cel - marketscreener.com
Gilead Completes $7.8 Billion Acquisition of Arcellx - Contract Pharma
Gilead Sciences Finalizes $7.8 Billion Acquisition of Arcellx - marketscreener.com
Recent Arcellx deal leaves Gilead Sciences stock consolidating amid persistent oversold signals - Traders Union
Gilead Sciences Completes $7.8 Billion Acquisition of Arcellx, Securing Full Control of CAR T Therapy Anito-cel - citybiz
Gilead Sciences Completes $7.8 Billion Acquisition of Arcellx to Accelerate Launch of Anito-cel CAR T Therapy for Multiple Myeloma 1 - Minichart
Arcellx (NASDAQ: ACLX) files to withdraw Nasdaq listing - Stock Titan
Gilead Sciences Completes Acquisition of Arcellx and Anito-cel - TipRanks
Gilead fully acquires Arcellx (NASDAQ: ACLX) as tender offer and merger close - Stock Titan
Arcellx (ACLX) to Merge with Gilead Unit for $115/Share plus CVR - Stock Titan
Gilead completes $7.8 billion acquisition of Arcellx - Investing.com
Gilead (NASDAQ: GILD) closes Arcellx deal, gains full control of anito-cel - Stock Titan
Gilead Sciences (ACLX) to close merger; 77.2% tendered, $115 cash plus CVR - Stock Titan
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel - Business Wire
Gilead Sciences to buy Arcellx in deal valued at $7.8 billion - MSN
Arcellx (NASDAQ:ACLX) Upgraded to Strong-Buy at Truist Financial - MarketBeat
Citigroup downgrades Arcellx (ACLX) - MSN
Arcellx, Inc.(NasdaqGS: ACLX) dropped from S&P TMI Index - marketscreener.com
Arcellx, Inc.(NasdaqGS: ACLX) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Arcellx, Inc.(NasdaqGS: ACLX) dropped from S&P Global BMI Index - marketscreener.com
Arcellx sinks following results from Kelonia CAR-T therapy for multiple myeloma - MSN
Are Medical Stocks Lagging Arcellx (ACLX) This Year? - Yahoo Finance
Gilead Sciences Obtains Regulatory Approval for Arcellx Acquisition - HarianBasis.co
ACLX Stock Price, Quote & Chart | ARCELLX INC (NASDAQ:ACLX) - ChartMill
Arcellx Inc Stock (ACLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arcellx Inc Stock (ACLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gilson Michelle | CHIEF FINANCIAL OFFICER |
Apr 16 '26 |
Option Exercise |
8.66 |
2,110 |
18,273 |
67,048 |
| Elghandour Rami | SEE REMARKS |
Jan 06 '26 |
Option Exercise |
0.00 |
55,991 |
0 |
782,467 |
| Elghandour Rami | SEE REMARKS |
Jan 03 '26 |
Option Exercise |
0.00 |
53,098 |
0 |
726,476 |
| Elghandour Rami | SEE REMARKS |
Jan 02 '26 |
Option Exercise |
0.00 |
55,459 |
0 |
673,378 |
| Elghandour Rami | SEE REMARKS |
Feb 27 '26 |
Sale |
113.92 |
89,916 |
10,243,267 |
276,051 |
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):